BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 11:29 (1895 d 05:41 ago) – Posting: # 20530
Views: 2,343

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,288 posts in 4,890 threads, 1,658 registered users;
14 visitors (0 registered, 14 guests [including 6 identified bots]).
Forum time: 16:10 CET (Europe/Vienna)

‘Normal science’ means research firmly based upon one or more
past scientific achievements, achievements that some particular
scientific community acknowledges for a time as supplying
the foundation for its further practice.    Thomas S. Kuhn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5